United Therapeutics says TETON-1 study published in NEJM

United Therapeutics (UTHR) Corporation announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. A summary of the publication was also presented today during a symposium at the annual meeting of the American Thoracic Society International Conference in Orlando. The use of nebulized Tyvaso for IPF has not been approved by the U.S. Food and Drug Administration and remains investigational for IPF. The results of TETON-1 were also presented at ATS during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session on Sunday, May 17. Combined results from TETON-1 and TETON-2 were presented today during an oral session at ATS. TETON-1 met its primary efficacy endpoint, with nebulized Tyvaso demonstrating statistically significant improvement in absolute FVC relative to placebo from baseline to week 52 in an IPF population broadly treated with background therapy. The median change in FVC at week 52 was -43.3 mL in the nebulized Tyvaso group and -196.2 mL in the placebo group; between-group difference was 130.1 mL.